JD Supra2d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Hosted on MSN7d
The FDA is about to make weight-loss drugs a lot harder to get
DeBenedetto's excitement has been stunted, however, by recent developments that will make compounded tirzepatide no longer ...
ENDPOINTS NEWS20h
Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
pharmaphorum2h
Ozempic is first GLP-1 drug FDA-approved for kidney disease
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
JD Supra13d
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
pulmonologyadvisor4d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
rheumatologyadvisor1d
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.
AOL7d
The FDA is about to make weight-loss drugs a lot harder to get
DeBenedetto's excitement has been stunted, however, by recent developments that will make compounded tirzepatide no longer widely available. The FDA has removed the drug from its shortage list and ...